Clinical advances in monoclonal antibody against PCSK9 for coronary atherosclerotic heart disease
10.3969/j.issn.1674-8115.2018.03.018
- Author:
Cong-Cong LUO
1
Author Information
1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Coronary atherosclerotic heart disease (CHD);
Hyperlipidemia;
Inhibitor;
Low-density lipoprotein-cholesterol (LDL-C);
Monoclonal antibody;
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(3):339-342
- CountryChina
- Language:Chinese
-
Abstract:
Coronary atherosclerotic heart disease (CHD) remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C can effectively reduce the risk of CHD. To date, lipid-lowering medicines such as statins are effective in lowering LDL-C, but a proportion of patients do not achieve lipid reduction target with statins or are intolerant to statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of agents reducing LDL-C which gain more and more concerns. Through inhibitory effect on PCSK9 and increasing low-density lipoprotein receptors recycling, they can significantly reduce serum LDL-C levels. PCSK9 inhibitors are currently in phase III of clinical trials, and the results showed that they had good lipid-lowering effects and tolerability. This review provided an overview of the latest advances and challenges about PCSK9 inhibitors.
